NCT07016464View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

March 29, 2026

Study Completion Date

March 29, 2026

Conditions
Healthy
Interventions
DRUG

REM0045392

Liquid formulation

DRUG

Placebo

Liquid formulation

Trial Locations (1)

2650

SGS Belgium NV - Clinical Pharmacology Unit, Edegem

Sponsors

Lead Sponsor

reMYND
All Listed Sponsors
lead

reMYND

INDUSTRY

NCT07016464 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. | Biotech Hunter | Biotech Hunter